drugset
drugset / Trial / NCT02932891

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

NCT02932891 ↗

Phase 2 Completed 28 enrolled Sun Pharmaceutical Industries, Inc.
NaSingle-groupOpen-labelTreatment

Summary

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic Dermatitis

Timeline

Start
2016-08
Primary completion
2017-04-14
Completion
2017-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject DSXS Unknown — Topical

Indications

atopic eczema